{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:10:44Z","timestamp":1792613444207,"version":"4.5.0"},"reference-count":100,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteasome inhibition has emerged as an important therapeutic strategy in multiple myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago, this first-in-class proteasome inhibitor (PI) has contributed substantially to the observed improvement in survival in MM patients over the past decade. Although first approved as a single agent in the relapsed setting, bortezomib is now predominantly used in combination regimens. Furthermore, the standard twice-weekly schedule may be replaced by weekly infusion, especially when bortezomib is used as part of combination regimens in frontline therapy. Indeed, bortezomib is an established component of induction therapy for patients eligible or ineligible for autologous stem cell transplantation. Bortezomib has also been incorporated into conditioning regimens before autologous stem cell transplantation, as well as into post-ASCT consolidation therapy, and in the maintenance setting. In addition, a new route of bortezomib administration, subcutaneous infusion, has recently been approved. Recently, several new agents have been introduced into the clinic, including carfilzomib, marizomib, and MLN9708, and trials investigating these \u201csecond-generation\u201d PIs in patients with relapsed\/refractory MMs have demonstrated positive results. This review provides an overview of the role of PIs in the treatment of MM, focusing on developments over the past decade.<\/jats:p>","DOI":"10.1182\/blood-2012-04-403733","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T22:09:16Z","timestamp":1338329356000},"page":"947-959","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":446,"title":["Proteasome inhibitors in multiple myeloma: 10 years later"],"prefix":"10.1182","volume":"120","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"Hematology Department, University Hospital Hotel-Dieu, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Policlinico S. Orsola-Malpighi, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Hospital Universitario Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Instituto de Biologia Molecular y Celular del C\u00e1ncer (Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas), Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Ematologia, Azienda Ospedaliero-Universitaria San Giovanni Battista, Ospedale Molinette, Torino, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[{"name":"Institut Canc\u00e9rologique de l'Ouest, Nantes\/St Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111809282707800_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell.","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2019111809282707800_B2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway.","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"issue":"24","key":"2019111809282707800_B3","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","article-title":"The ubiquitin-proteasome pathway: on protein death and cell life.","volume":"17","author":"Ciechanover","year":"1998","journal-title":"EMBO J"},{"issue":"6624","key":"2019111809282707800_B4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution.","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"issue":"12","key":"2019111809282707800_B5","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111809282707800_B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1054\/drup.1999.0095","article-title":"Proteasome inhibitors as potential novel anticancer agents.","volume":"2","author":"Dou","year":"1999","journal-title":"Drug Resist Updat"},{"issue":"5","key":"2019111809282707800_B7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target.","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111809282707800_B8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"2019111809282707800_B9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CE.S13838","article-title":"Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.","volume":"6","author":"Jain","year":"2011","journal-title":"Core Evid"},{"issue":"5","key":"2019111809282707800_B10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019111809282707800_B11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int"},{"issue":"9","key":"2019111809282707800_B12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdq009","article-title":"Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.","volume":"21","author":"Reddy","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111809282707800_B13","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"2019111809282707800_B14","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.","volume":"16","author":"Wright","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111809282707800_B15","article-title":"Impact of bortezomib on bone health in myeloma: a review of current evidence [published online ahead of print January 6, 2012].","author":"Zangari","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"2019111809282707800_B16","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111809282707800_B17","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"2019111809282707800_B18","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111809282707800_B19","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2019111809282707800_B20","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111809282707800_B21","first-page":"1253","article-title":"Epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable ONX 0912 have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects [abstract].","volume":"118","author":"Hurchla","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111809282707800_B22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib.","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111809282707800_B23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.","volume":"11","author":"Potts","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"2019111809282707800_B24","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111809282707800_B25","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111809282707800_B26","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.","volume":"22","author":"Papandreou","year":"2004","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111809282707800_B27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111809282707800_B28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111809282707800_B29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111809282707800_B30","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111809282707800_B31","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111809282707800_B32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"issue":"2","key":"2019111809282707800_B33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuro.2007.11.003","article-title":"Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro.","volume":"29","author":"Csizmadia","year":"2008","journal-title":"Neurotoxicology"},{"issue":"11","key":"2019111809282707800_B34","first-page":"2646a","article-title":"Proteasome inhibitor associated neuropathy is mechanism based [abstract].","volume":"112","author":"Silverman","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111809282707800_B35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111809282707800_B36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2019111809282707800_B37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma.","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"2019111809282707800_B38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/asheducation-2010.1.423","article-title":"Dealing with neuropathy in plasma-cell dyscrasias.","author":"Sonneveld","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2019111809282707800_B39","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111809282707800_B40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"34","key":"2019111809282707800_B41","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111809282707800_B42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111809282707800_B43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A practical update on the use of bortezomib in the management of multiple myeloma.","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"issue":"12","key":"2019111809282707800_B44","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111809282707800_B45","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"issue":"3-4","key":"2019111809282707800_B46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib retreatment in relapsed multiple myeloma: results from a retrospective multicentre survey in Germany and Switzerland.","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"issue":"s2","key":"2019111809282707800_B47","article-title":"Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study [abstract].","volume":"95","author":"Petrucci","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2019111809282707800_B48","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2019111809282707800_B49","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"issue":"25","key":"2019111809282707800_B50","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111809282707800_B51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2019111809282707800_B52","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone.","volume":"91","author":"Jagannath","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111809282707800_B53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br J Haematol"},{"issue":"s2","key":"2019111809282707800_B54","first-page":"420","article-title":"Bortezomib (VELCADE)-thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation [abstract].","volume":"96","author":"Garderet","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"2019111809282707800_B55","first-page":"368","article-title":"Vantage 088. Vorinostat in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: results of a global, randomized phase 3 trial [abstract].","volume":"118","author":"Dimopoulos","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111809282707800_B56","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma.","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111809282707800_B57","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study.","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111809282707800_B58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"2019111809282707800_B59","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111809282707800_B60","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111809282707800_B61","first-page":"221","article-title":"Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial [abstract].","volume":"118","author":"San Miguel","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B62","first-page":"222","article-title":"Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial [abstract].","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111809282707800_B63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/10428190903452826","article-title":"Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.","volume":"51","author":"Corso","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111809282707800_B64","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"2019111809282707800_B65","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br J Haematol"},{"issue":"30","key":"2019111809282707800_B66","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809282707800_B67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10245330701214236","article-title":"Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology"},{"issue":"30","key":"2019111809282707800_B68","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809282707800_B69","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111809282707800_B70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2019111809282707800_B71","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"9758","key":"2019111809282707800_B72","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"2019111809282707800_B73","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"s1","key":"2019111809282707800_B74","article-title":"Results of pre- and post-autologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib (VBMCP\/VBAD\/V) [abstract].","volume":"96","author":"Rosi\u00f1ol","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"2019111809282707800_B75","first-page":"23","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract].","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"23","key":"2019111809282707800_B76","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111809282707800_B77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111809282707800_B78","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"s1","key":"2019111809282707800_B79","article-title":"Improved progression-free survival with bortezomib consolidation after high dose melphalan: results of a randomized phase III trial [abstract].","volume":"96","author":"Mellqvist","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2019111809282707800_B80","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111809282707800_B81","first-page":"376","article-title":"Long-term results of the GIMEMA VTD consolidation trial in autografted multiple myeloma patients (VEL-03-096): impact of minimal residual disease detection by real time quantitative PCR on late recurrences and overall survival [abstract].","volume":"118","author":"Ladetto","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B82","first-page":"816","article-title":"Superior complete response rate (CR) and progression-free survival (PFS) with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologous stem-cell transplantation (ASCT) in multiple myeloma (MM) [abstract].","volume":"118","author":"Cavo","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111809282707800_B83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbmt.2011.12.580","article-title":"Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.","volume":"18","author":"Sahebi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2019111809282707800_B84","first-page":"1694","article-title":"A phase III PETHEMA\/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: superiority of bortezomib\/thalidomide compared with thalidomide and alfa-2b interferon [abstract].","volume":"118","author":"Rosi\u00f1ol","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111809282707800_B85","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma [published online ahead of print May 3, 2012].","author":"Vij","journal-title":"Blood"},{"issue":"15s","key":"2019111809282707800_B86","first-page":"573s","article-title":"Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [abstract].","volume":"28","author":"Vij","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111809282707800_B87","first-page":"819","article-title":"Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract].","volume":"118","author":"Singhal","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B88","first-page":"433","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract].","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111809282707800_B89","first-page":"iv122","article-title":"Responses to single-agent carfilzomib (CFZ) are not affected by cytogenetics in patients (pts) with relapsed and refractory multiple myeloma (R\/R MM) [abstract].","volume":"22","author":"Jakubowiak","year":"2011","journal-title":"Ann Oncol"},{"issue":"22","key":"2019111809282707800_B90","first-page":"128","article-title":"Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM) [abstract].","volume":"114","author":"Niesvizky","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B91","first-page":"290","article-title":"Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM): a trial of the European Myeloma Network EMN [abstract].","volume":"118","author":"Sonneveld","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"2019111809282707800_B92","first-page":"288","article-title":"Final results of a frontline phase 1\/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM) [abstract].","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B93","first-page":"140","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM) [abstract].","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B94","first-page":"1148","article-title":"MLN9708, a novel, investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma: results of a phase 1 dose-escalation study [abstract].","volume":"118","author":"Assouline","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B95","first-page":"223","article-title":"Phase 1\/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) [abstract].","volume":"118","author":"Berdeja","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B96","first-page":"371","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and\/or refractory multiple myeloma: results from a phase 1 dose-escalation study [abstract].","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111809282707800_B97","first-page":"140","article-title":"Investigational agent MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and\/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study [abstract].","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111809282707800_B98","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial.","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"2019111809282707800_B99","first-page":"222","article-title":"Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract].","volume":"118","author":"Niesvizky","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"15s","key":"2019111809282707800_B100","first-page":"435s","article-title":"Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract].","volume":"27","author":"Jagannath","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/947\/1362187\/zh803112000947.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/947\/1362187\/zh803112000947.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T21:18:58Z","timestamp":1743196738000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/5\/947\/30255\/Proteasome-inhibitors-in-multiple-myeloma-10-years"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,2]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-403733","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,2]]}}}